Shattuck Labs Secures $103M to Accelerate First-In-Class IBD & Autoimmune Therapy Innovations

Shattuck Labs is excited to announce a significant milestone in our journey toward advancing innovative therapeutics for inflammatory diseases with a successful funding round that raised $103,000,000. This investment underscores the growing confidence in our vision of transforming the management of Inflammatory Bowel Disease (IBD) and other inflammatory autoimmune conditions through groundbreaking science. Based in both Austin, Texas, and Durham, North Carolina, Shattuck Labs has positioned itself as a leader in biotechnology by leveraging our deep expertise in protein engineering to pioneer novel therapeutic solutions. The recent capital infusion is strategically targeted to accelerate the development and clinical evaluation of our lead program, SL-325, a potentially first-in-class DR3 antagonist antibody that promises a complete and more durable blockade of the clinically validated TL1A/DR3 pathway. Our innovative approach not only aims to achieve long-term remission for IBD patients but also holds potential for broader applications in treating inflammatory conditions that significantly impact patient quality of life. The robust funding will enable us to further optimize our antibody’s design, expand our preclinical and clinical research programs, and enhance our operational capabilities across our dual locations. This achievement reflects both the strength of our scientific foundation and the commitment of our investors to addressing unmet medical needs with high precision and care. As we embark on this exciting phase, Shattuck Labs is more dedicated than ever to pushing the boundaries of conventional treatment methods and delivering transformational therapies that have the potential to redefine patient care in the field of immunology and beyond.